Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone

Psychoneuroendocrinology

Volumn 25, Issue 5, 2000, Pages 513-518

  Heuser, Isabella ^a   Deuschle, Michael ^a   Weber, Bettina ^a   Stalla, Günter K ^a   Holsboer, Florian ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Aging; DEX CRH test; DST; HPA; MR antagonist; Spironolactone

Indexed keywords

CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; HYDROCORTISONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE;

ADULT; AGING; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; ENDOCRINE SYSTEM EXAMINATION; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NORMAL HUMAN; PRIORITY JOURNAL; PROVOCATION TEST; REGULATORY MECHANISM; VOLUNTEER;

ADRENAL GLANDS; ADRENOCORTICOTROPIC HORMONE; ADULT; CORTICOTROPIN-RELEASING HORMONE; DEXAMETHASONE; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; HYPOTHALAMUS; PITUITARY GLAND; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE;

EID: 0034113351     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(00)00006-8     Document Type: Article

References (13)

1. von Bardeleben U., Holsboer F. Cortisol response to a combined dexamethasone-human corticotropin-releasing-hormone challenge in patients with depression. J. Neuroendocrinol. 1:1989;485-488.
2. Bradbury M.J., Akana S.F., Dallman M.F. Roles of type I and II corticosteroid receptors in the regulation of basal activity in the hypothalamo-pituitary-adrenal axis during the diurnal through and the peak: evidence for a nonadditive effect of combined receptor occupation. Endocrinology. 134:1994;1286-1296.
3. Dallman M.F., Levin N., Cascio C.S., Akana S.F., Jacobson L., Kuhn R.W. Pharmacological evidence that the inhibition of diurnal adrenocorticotropin secretion by corticosteroids is mediated via type I corticosterone-preferring receptors. Endocrinology. 124:1989;2844-2850.
4. Dayanithi G., Antoni F.A. Rapid as well as delayed inhibition of pituitary adrenocorticotropic hormone release by glucocorticoids is mediated by type II glucocorticoid receptors and requires newly synthesized messenger ribonucleic acids as well as protein. Endocrinology. 125:1989;308-313.
5. Dodt C., Kern W., Fehm H.L., Born J. Antimineralocorticoid canrenoate enhances secretory activity of the hypothalamus-pituitary-adrenocortical (HPA) axis in humans. Neuroendocrinology. 58:1993;570-574.
6. Heuser I., Yassouridis A., Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J, Psychiat. Res. 28:1994;341-356.
7. Heuser I., Gotthardt U., Schweiger U., Schmider J., Lammers C.H., Dettling M., Holsboer F. Age-associated changes of pituitary-adrenocortical hormone regulation in humans: importance of gender. Neurobiol. Aging. 15:1994;227-231.
8. Heuser I., Schweiger U., Gotthardt U., Schmider J., Lammers C.H., Dettling M., Holsboer F. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am. J. Psychiatry. 153:1996;93-99.
9. Holsboer F., Spengler D., Heuser I. The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia. Progr. Brain Res. 93:1992;385-417.
10. de Kloet E.R. Brain corticosteroid receptor balance and homeostatic control. Front Neuroendocrinol. 12:1991;95-164.
11. Ratka A., Sutanto W., Bloemers M., de Kloet E.R. On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation. Neuroendocrinology. 50:1989;117-123.
12. Reul J.M.H.M., Probst J.C., Skutella T., Hirschmann M., Stec I.S.M., Montkowski A., Landgraf R., Holsboer F. Increased stress-induced adrenocorticotropin response after long-term intracerebroventricular treatment of rats with antisense mineralocorticoid receptor oligodeoxynucleotides. Neuroendocrinology. 65:1997;189-199.
13. Rupprecht R., Reul J.M.H.M., van Steensel B., Spengler D., Söder M., Berning B., Holsboer F., Damm K. Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur. J. Pharmacol. 247:1993;145-154.